Merck has announced that its Life Science business sector has been awarded a €121 million contract award for the construction of a lateral flow membrane production facility over a three-year period at the company’s U.S. site in Sheboygan, Wisconsin. 

 

The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness.

 

“With this agreement, Merck will construct a state-of-the-art lateral flow membrane production facility that will give our global in-vitro diagnostic (IVD) manufacturing customers greater flexibility and security of supply of our Hi-Flow Plus lateral flow membranes,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science.

 

“Our lateral flow membranes have earned a worldwide reputation for high consistency among rapid diagnostic manufacturers and the already robust global demand for this membrane has significantly increased since the onset of the pandemic. With this critical investment, we are expanding much-needed access to essential diagnostic testing as a trusted partner to the world’s most sophisticated diagnostic manufacturers,” said Jean-Charles Wirth, head of Applied Solutions, Life Science at Merck.

 

Building this new facility supports Merck’s overall Life Science strategy to add physical capacity and expand its regional network to enable further growth of its key portfolios.

 

Hi-Flow Plus Lateral flow membrane is used in rapid diagnostic test kit manufacturing by Merck’s customers, enabling reproducible results due to its consistent quality and optimized properties. The rapid test kits are used for a variety of applications, including Infectious Disease testing (Covid-19, HIV, Influenza, Malaria, etc.), as well as in women’s health, biomarker detection, drug testing, food safety and animal health. Due to continuously increasing demand for lateral flow membrane, Merck had already invested in a second membrane casting line in Cork, Ireland, which was recently completed, and expanded the range of other critical reagents (antibodies, beads, blockers, buffers) utilized to develop lateral flow rapid test kits. These strategic investments position Merck as an important critical raw material supplier for the Diagnostic market, especially as the company prepares for IVD Regulation and Medical Device Regulation.

 

Merck’s Life Science business is undertaking an ambitious, multi-year program to increase production capacity and capabilities to support the growing global demand for lifesaving vaccines, therapies and diagnostics. Within the last year, the company has accelerated investments to expand capacity to produce its support Mobius single-use assemblies in both the U.S. and France, as well as increased capacity for the production of cell culture media in the U.S. and UK, among others. Additionally, several expansion projects continue to advance across the company’s manufacturing and distribution global network.